IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers
01 Septembre 2022 - 3:44PM
IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the
“Company”), announces today it is accepting patients for medical
weight loss services at IMAC Regeneration Centers. The medical
weight loss service will launch in three facilities this month.
“We are excited about the launch of medical
weight loss in IMAC Regeneration Centers. There was significant
effort applied to develop and launch this service and we believe it
can have a significant impact on our patients’ rehabilitative
process while also introducing new patients to the IMAC orthopedic
service line,” said Jeffrey Ervin, IMAC’s Chief Executive Officer.
“Obesity is the second leading cause of back pain. Therefore,
implementing the weight loss service gives us another tool to
assist consumers in their battle against chronic back pain.”
The American Journal of Preventative Medicine
estimates that 42% of US adults will be obese by 2030.
The medical weight loss service is administered
by medical doctors and nurse practitioners that deliver injection
based therapies for metabolic improvement and fat reduction. The
program is customized to accommodate each person and typically
ranges from $1,500 to $4,000 per year.
About IMAC Holdings, Inc.
IMAC Holdings owns and manages health and
wellness centers that deliver sports medicine, orthopedic care, and
restorative joint and tissue therapies for movement restricting
pain and neurodegenerative diseases. IMAC is comprised of
three business segments: outpatient medical centers, The Back
Space, and a clinical research division. With treatments to address
both young and aging populations, IMAC Holdings owns or
manages outpatient medical clinics that deliver regenerative
rehabilitation services as a minimally invasive approach to acute
and chronic musculoskeletal and neurological health problems.
IMAC’s The Back Company retail spinal health and wellness treatment
centers deliver chiropractic care within Walmart locations. IMAC’s
research division is currently conducting a Phase I clinical trial
evaluating a mesenchymal stem cell therapy candidate for
bradykinesia due to Parkinson’s disease. For more information
visit www.imacholdings.com.
###
Safe Harbor Statement
This press release contains forward-looking
statements. These forward-looking statements, and terms such as
“anticipate,” “expect,” “believe,” “may,” “will,” “should” or other
comparable terms, are based largely
on IMAC's expectations and are subject to a number of
risks and uncertainties, certain of which are
beyond IMAC's control. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, risks and uncertainties associated with its
ability to maintain and grow its business, variability of operating
results, its ability to maintain and enhance its brand, its
development and introduction of new products and services, the
successful integration of acquired companies, technologies and
assets, marketing and other business development initiatives,
competition in the industry, general government regulation,
economic conditions, dependence on key personnel, the ability to
attract, hire and retain personnel who possess the skills and
experience necessary to meet customers’ requirements, and its
ability to protect its intellectual
property. IMAC encourages you to review other factors
that may affect its future results in its registration statement
and in its other filings with the Securities and Exchange
Commission. In light of these risks and uncertainties, there can be
no assurance that the forward-looking information contained in this
press release will in fact occur.
IMAC Press Contact:Laura Fristoelfristoe@imacrc.com
IMAC (NASDAQ:IMACW)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
IMAC (NASDAQ:IMACW)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024